Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › INBX

Inhibrx Biosciences

INBX Lead: NDA Submitted 3 Biotech Distilled articles ↓ 18 filings & releases ↓ Cash $133M (Jun 30, 2026) ↓ 3 verdicts ↓ 1 timing quote ↓
Oncology Protein

Market cap $1.24B 14.7M shares (10-Q, Aug 7, 2026) × $84.52 close Nov 6, 2026

Most recent annual filing: 2026-03-19

Catalyst timeline

6 trackedQuarter catalyst calendar →
  1. Ozekibart FDA feedback4Q 2026Ozekibart FDA feedback, 4Q 2026, notable
  2. Ozekibart interim1Q 2027Ozekibart interim, 1Q 2027, notable
  3. INBRX-106 trial start2027INBRX-106 trial start, 2027, notable
  4. Ozekibart enrollment done2027Ozekibart enrollment done, 2027, routine
  5. Ozekibart PDUFA dateApr 14, 2027Ozekibart PDUFA date, Apr 14, 2027, major
  6. INBRX-106 interim2H 2027INBRX-106 interim, 2H 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

Technology platforms

sdAb

Proprietary single-domain antibody (sdAb) engineering platform enabling high-order receptor clustering through multivalent formats; used to develop hexavalent and other precision-valency biologic candidates

Targets: OX40

Capital (as filed)

Cash
$133M cash and cash equivalents · Jun 30, 2026 (10-Q)
Operating cash flow
−$29.9M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$220M cash per the update of Sep 8, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (3)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (3 calls)

Every verdict Biotech Distilled has published on Inhibrx Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-09-03 Speculative buy speculative Inhibrx Biosciences (INBX) — Scientific Deep Dive for INBRX-106, Ozekibart (INBRX-109) and Pipeline Products The biology is more de-risked than any OX40 or DR5 program has ever been, with a first-in-disease PDUFA floor and a hexavalent OX40 agonist producing the first randomized ORR delta and matched pharmacodynamic signal in the class, but the capital structure puts $275M of secured debt ahead of the equity and the headline efficacy rests on eleven responders in an open-label arm.
  2. 2026-09-04 Speculative buy speculative UPDATE: Inhibrx Biosciences (INBX) - The Clock Is Set for Tuesday, 5:00 a.m. PT The thesis is unchanged ahead of the September 8 PFS readout: two shots on goal with a floor under them, sized as a 1–2% of book total-loss-capable expression of a format thesis about to be tested on a clock rather than a snapshot.
  3. 2026-09-08 Speculative buy speculative UPDATE: Inhibrx Biosciences (INBX) - The Curve Separated. The Stock Fell Anyway. The valency thesis produced what no bivalent OX40 program ever did — a 4.7-month median PFS separation and improved ORR on a cleaner analysis population — but no hazard ratio was disclosed, the Phase 3 slipped behind an expansion cohort and FDA meeting, and the stock fell 5.6% on the best OX40 data ever generated; the position remains a 1–2% of book, total-loss-capable expression.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (18)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Sep 4, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)